

List of tables for EvaluatePharma Yearbook 2008

Chapter 1: Company performance

- 1.1: Total Rx & OTC sales, top 150 companies, 2006-2007
- 1.2: Net income. top 150 companies, 2006-2007
- 1.3: Normalised net income, top 150 companies, 2006-2007
- 1.4: Market capitalisation, top 150 companies, 2006-2007
- 1.5: Employee numbers, top 150 companies, 2006-2007
- 1.6: Cash in the bank, top 150 companies, 2006-2007
- 1.7: R&D expenditure, top 150 companies, 2006-2007
- 1.8: SG&A expenditure, top 150 companies, 2006-2007
- 1.9: CoGS expenditure, top 150 companies, 2006-2007

Chapter 2. Performance analysis

2.1: companies earning > \$10 billion

- 2.1.1: Growth rankings for total Rx & OTC sales
- 2.1.2: Growth rankings for normalised net income
- 2.1.3: Growth rankings for market cap and share price
- 2.1.4: Rankings of price-earnings ratios
- 2.1.5: Mergers and acquisitions

2.2: companies earning \$1 billion - \$10 billion

- 2.2.1: Growth rankings for total Rx & OTC sales
- 2.2.2: Growth rankings for normalised net income
- 2.2.3: Growth rankings for market cap and share price
- 2.2.4: Rankings of price-earnings ratios
- 2.2.5: Mergers and acquisitions

2.3: companies earning < \$10 billion

- 2.3.1: Growth rankings for total Rx & OTC sales
- 2.3.2: Growth rankings for normalised net income
- 2.3.3: Growth rankings for market cap and share price
- 2.3.4: Rankings of price-earnings ratios
- 2.3.5: Mergers and acquisitions

Chapter 3. Operational efficiency

- 3.1: Group R&D spend and as a proportion of sales, by business sector, 2006-2007
- 3.2: Group SG&A spend and as a proportion of sales, by business sector, 2006-2007
- 3.3: Group CoGS spend and as a proportion of sales, by business sector, 2006-2007

Chapter 4. Shifting sands

- 4.1: Worldwide sales by therapeutic area, 2000-2007
- 4.2: Winners and losers: companies showing the best and worst 2007 sales growth in 12 therapeutic areas
- 4.3: Generics company sales, 2006-2007

Chapter 5. Strategic thinking

- 5.1: Worldwide sales by technology, 2000-2007
- 5.2: Biotech sales, 2006-2007
- 5.3: Worldwide sales by strategy, 2000-2007
- 5.4: Company sales by strategy, 2006-2007
- 5.5: Worldwide sales by US patent risk, 2000-2007

Chapter 6. Market developments

6.1: FDA approvals and research products abandoned, 2003-2007

6.2: US patent expiries of products with US sales of more than \$100 million (2007-2011) showing US annual sales, 2007

6.3: Major licensing deals in 2007

Appendix 1

Total pharmaceutical sales (2007) showing sales from Rx, OTC, total Rx & OTC, alliance/co-promotion, royalty & licensing and other pharma (including bulk sales)

Appendix 2.1

Top companies by market capitalisation

Appendix 2.2

Top companies by sector

Appendix 2.3

Top companies by country

Appendix 3

Company profiles